{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:05:44Z","timestamp":1790503544416,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R15CA161486"],"award-info":[{"award-number":["1R15CA161486"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001159","name":"Hawaii Community Foundation","doi-asserted-by":"publisher","award":["14ADVC-64563"],"award-info":[{"award-number":["14ADVC-64563"]}],"id":[{"id":"10.13039\/100001159","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12943-015-0390-5","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T23:08:27Z","timestamp":1433977707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Osteoprotegerin in breast cancer: beyond bone remodeling"],"prefix":"10.1186","volume":"14","author":[{"given":"Michael","family":"Weichhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Tsang Mui","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"issue":"2","key":"390_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309\u201319.","journal-title":"Cell"},{"issue":"1","key":"390_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","volume":"234","author":"E Tsuda","year":"1997","unstructured":"Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234(1):137\u201342.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"390_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10549-005-2419-8","volume":"92","author":"I Holen","year":"2005","unstructured":"Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo\u2013a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207\u201315. doi:10.1007\/s10549-005-2419-8.","journal-title":"Breast Cancer Res Treat"},{"key":"390_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23737","author":"HS Park","year":"2014","unstructured":"Park HS, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol. 2014. doi:10.1002\/jso.23737.","journal-title":"J Surg Oncol"},{"issue":"1\u20132","key":"390_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0378-1119(97)00509-X","volume":"204","author":"KB Tan","year":"1997","unstructured":"Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 1997;204(1\u20132):35\u201346.","journal-title":"Gene"},{"issue":"9","key":"390_CR6","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1074\/jbc.273.9.5117","volume":"273","author":"K Yamaguchi","year":"1998","unstructured":"Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273(9):5117\u201323.","journal-title":"J Biol Chem"},{"issue":"3","key":"390_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","volume":"247","author":"A Mizuno","year":"1998","unstructured":"Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun. 1998;247(3):610\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"390_CR8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260\u20138.","journal-title":"Genes Dev"},{"issue":"2","key":"390_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165\u201376.","journal-title":"Cell"},{"issue":"7","key":"390_CR10","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597\u2013602.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"390_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61\u20136.","journal-title":"Br J Cancer"},{"issue":"8 Suppl","key":"390_CR12","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588\u201394.","journal-title":"Cancer"},{"issue":"6","key":"390_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12(6):215. doi:10.1186\/bcr2781.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"390_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","volume":"18","author":"WC Dougall","year":"2012","unstructured":"Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012;18(2):326\u201335. doi:10.1158\/1078-0432.CCR-10-2507.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"390_CR15","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001;61(11):4432\u20136.","journal-title":"Cancer Res"},{"key":"390_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29439","author":"PD Ottewell","year":"2015","unstructured":"Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL, et al. OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer. 2015. doi:10.1002\/ijc.29439.","journal-title":"Int J Cancer"},{"issue":"3 Suppl","key":"390_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cncr.11138","volume":"97","author":"JJ Body","year":"2003","unstructured":"Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97(3 Suppl):887\u201392. doi:10.1002\/cncr.11138.","journal-title":"Cancer"},{"issue":"5","key":"390_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401\u201319. doi:10.1038\/nrd3705.","journal-title":"Nat Rev Drug Discov"},{"issue":"35","key":"390_CR19","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139. doi:10.1200\/JCO.2010.29.7101.","journal-title":"J Clin Oncol"},{"issue":"10","key":"390_CR20","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","volume":"140","author":"RJ Thomas","year":"1999","unstructured":"Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140(10):4451\u20138. doi:10.1210\/endo.140.10.7037.","journal-title":"Endocrinology"},{"issue":"5","key":"390_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00018-008-8536-x","volume":"66","author":"G Zauli","year":"2009","unstructured":"Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci. 2009;66(5):841\u201351. doi:10.1007\/s00018-008-8536-x.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"390_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jcp.2005.026534","volume":"59","author":"C Van Poznak","year":"2006","unstructured":"Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol. 2006;59(1):56\u201363. doi:10.1136\/jcp.2005.026534.","journal-title":"J Clin Pathol"},{"issue":"3","key":"390_CR23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.bbrc.2008.01.118","volume":"368","author":"TD Rachner","year":"2008","unstructured":"Rachner TD, Schoppet M, Niebergall U, Hofbauer LC. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun. 2008;368(3):736\u201341. doi:10.1016\/j.bbrc.2008.01.118.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"390_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/jcb.22232","volume":"108","author":"TD Rachner","year":"2009","unstructured":"Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, et al. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem. 2009;108(1):106\u201316. doi:10.1002\/jcb.22232.","journal-title":"J Cell Biochem"},{"issue":"22","key":"390_CR25","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687\u201390.","journal-title":"J Biol Chem"},{"issue":"6","key":"390_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673\u201382.","journal-title":"Immunity"},{"issue":"23","key":"390_CR27","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"JG Emery","year":"1998","unstructured":"Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"390_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jbmr.244","volume":"26","author":"I Zinonos","year":"2011","unstructured":"Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, et al. Anticancer efficacy of Apo2L\/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res. 2011;26(3):630\u201343. doi:10.1002\/jbmr.244.","journal-title":"J Bone Miner Res"},{"issue":"43","key":"390_CR29","doi-asserted-by":"publisher","first-page":"31601","DOI":"10.1074\/jbc.M706078200","volume":"282","author":"S Vitovski","year":"2007","unstructured":"Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007;282(43):31601\u20139. doi:10.1074\/jbc.M706078200.","journal-title":"J Biol Chem"},{"issue":"7","key":"390_CR30","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-05-3119","volume":"66","author":"JL Fisher","year":"2006","unstructured":"Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 2006;66(7):3620\u20138. doi:10.1158\/0008-5472.CAN-05-3119.","journal-title":"Cancer Res"},{"issue":"12","key":"390_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/cgt.2010.47","volume":"17","author":"JJ Cody","year":"2010","unstructured":"Cody JJ, Rivera AA, Lyons GR, Yang SW, Wang M, Sarver DB, et al. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther. 2010;17(12):893\u2013905. doi:10.1038\/cgt.2010.47.","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"390_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4):215. doi:10.1186\/bcr2889.","journal-title":"Breast Cancer Res"},{"issue":"17","key":"390_CR33","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-11-1431","volume":"71","author":"A Fradet","year":"2011","unstructured":"Fradet A, Sorel H, Bouazza L, Goehrig D, Depalle B, Bellahcene A, et al. Dual function of ERRalpha in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res. 2011;71(17):5728\u201338. doi:10.1158\/0008-5472.CAN-11-1431.","journal-title":"Cancer Res"},{"issue":"2","key":"390_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3892\/ijo.2014.2468","volume":"45","author":"I Zinonos","year":"2014","unstructured":"Zinonos I, Luo KW, Labrinidis A, Liapis V, Hay S, Panagopoulos V, et al. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int J Oncol. 2014;45(2):532\u201340. doi:10.3892\/ijo.2014.2468.","journal-title":"Int J Oncol"},{"issue":"5","key":"390_CR35","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cam4.277","volume":"3","author":"M Weichhaus","year":"2014","unstructured":"Weichhaus M, Segaran P, Renaud A, Geerts D, Connelly L. Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer medicine. 2014;3(5):1112\u201325. doi:10.1002\/cam4.277.","journal-title":"Cancer medicine"},{"issue":"8","key":"390_CR36","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/ijc.21606","volume":"118","author":"SS Cross","year":"2006","unstructured":"Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, et al. Osteoprotegerin (OPG)\u2013a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901\u20138. doi:10.1002\/ijc.21606.","journal-title":"Int J Cancer"},{"key":"390_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1476-4598-8-49","volume":"8","author":"PE Reid","year":"2009","unstructured":"Reid PE, Brown NJ, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer. 2009;8:49. doi:10.1186\/1476-4598-8-49.","journal-title":"Mol Cancer"},{"issue":"1","key":"390_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0609.2010.01446.x","volume":"85","author":"M Kobayashi-Sakamoto","year":"2010","unstructured":"Kobayashi-Sakamoto M, Isogai E, Holen I. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol. 2010;85(1):26\u201335. doi:10.1111\/j.1600-0609.2010.01446.x.","journal-title":"Eur J Haematol"},{"issue":"3","key":"390_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10456-013-9337-x","volume":"16","author":"Z Benslimane-Ahmim","year":"2013","unstructured":"Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, et al. Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis. 2013;16(3):575\u201393. doi:10.1007\/s10456-013-9337-x.","journal-title":"Angiogenesis"},{"issue":"1","key":"390_CR40","first-page":"199","volume":"33","author":"S Owen","year":"2013","unstructured":"Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG. Expression profile of receptor activator of nuclear-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33(1):199\u2013206.","journal-title":"Anticancer Res"},{"issue":"4","key":"390_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019234","volume":"6","author":"D Santini","year":"2011","unstructured":"Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011;6(4), e19234. doi:10.1371\/journal.pone.0019234.","journal-title":"PLoS One"},{"issue":"7","key":"390_CR42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.molonc.2014.04.003","volume":"8","author":"N Sanger","year":"2014","unstructured":"Sanger N, Ruckhaberle E, Bianchini G, Heinrich T, Milde-Langosch K, Muller V, et al. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. Mol Oncol. 2014;8(7):1196\u2013207. doi:10.1016\/j.molonc.2014.04.003.","journal-title":"Mol Oncol"},{"key":"390_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2407-13-40","volume":"13","author":"JT Ney","year":"2013","unstructured":"Ney JT, Juhasz-Boess I, Gruenhage F, Graeber S, Bohle RM, Pfreundschuh M, et al. Genetic polymorphism of the OPG gene associated with breast cancer. BMC Cancer. 2013;13:40. doi:10.1186\/1471-2407-13-40.","journal-title":"BMC Cancer"},{"key":"390_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-015-2352-z","author":"HS Omar","year":"2015","unstructured":"Omar HS, Shaker OG, Nassar YH, Marzouk SA, ElMarzouky MS. The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. Mol Cell Biochem. 2015. doi:10.1007\/s11010-015-2352-z.","journal-title":"Mol Cell Biochem"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-015-0390-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0390-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T14:19:47Z","timestamp":1630592387000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-015-0390-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s12943-015-0390-5","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]},"assertion":[{"value":"26 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"117"}}